Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD)

被引:30
|
作者
Sellmann, Cathrin [1 ]
Jin, Cheng Jun [1 ]
Engstler, Anna Janina [1 ]
De Bandt, Jean-Pascal [2 ,3 ]
Bergheim, Ina [1 ]
机构
[1] Friedrich Schiller Univ Jena, Inst Nutr Sci, SD Model Syst Mol Nutr, Dornburger Str 29, D-07743 Jena, Germany
[2] Paris Descartes Univ, Sorbonne Paris Cite, Nutr Biol Lab EA4466, Fac Pharm, Paris, France
[3] Paris Ctr Univ Hosp, APHP, Clin Chem Dept, Paris, France
关键词
Citrulline; Intestinal barrier function; Endotoxin; Occludin; Non-alcoholic fatty liver disease; TOLL-LIKE RECEPTORS; INSULIN-RESISTANCE; NITRIC-OXIDE; STEATOHEPATITIS; ARGININE; REPERFUSION; PROGRESSION; PREVALENCE; WATERMELON; NUTRITION;
D O I
10.1007/s00394-016-1287-9
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Purpose Impairments of intestinal barrier function are discussed as risk factors for the development and progression of non-alcoholic fatty liver disease (NAFLD). Studies suggest an association between arginine/citrulline homeostasis and the development of liver damages. Here, the effect of an oral l-citrulline (Cit) supplement on the development of a Western-style diet (WSD)-induced NAFLD was determined in mice. Methods Female 6- to 8-week-old C57BL/6J mice were either pair-fed a liquid Western-style or control diet (C) +/- 2.5 g/kg bodyweight Cit for 6 weeks (C + Cit or WSD + Cit). Indices of liver damage, glucose metabolism, intestinal barrier function and NO synthesis were measured. Results While bodyweight gain was similar between groups, markers of glucose metabolism like fasting blood glucose and HOMA index and markers of liver damage like hepatic triglyceride levels, number of neutrophils and plasminogen activator inhibitor-1 protein levels were significantly lower in WSD + Cit-fed mice when compared to WSD-fed mice only. Protein levels of the tight junction proteins occludin and zonula occludens-1 in duodenum were significantly lower in mice fed a WSD when compared to those fed a WSD + Cit (-similar to 70 and -similar to 60 %, respectively, P < 0.05), whereas portal endotoxin levels, concentration of 3-nitrotyrosine protein adducts in duodenum and toll-like receptor-4 mRNA expression in livers of WSD + Cit-fed mice were markedly lower than in WSD-fed mice (-similar to 43 %, P = 0.056; -similar to 80 and -similar to 48 %, respectively, P < 0.05). Conclusion Our data suggest that the protective effects of supplementing Cit on the development of NAFLD in mice are associated with a decreased translocation of endotoxin into the portal vein.
引用
收藏
页码:2519 / 2527
页数:9
相关论文
共 50 条
  • [41] Leptin as a marker of liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
    Petrovic, LM
    Alba, LM
    Lindor, KD
    Talwakar, JA
    Angulo, P
    MODERN PATHOLOGY, 2003, 16 (01) : 283A - 283A
  • [42] Liver Biopsy and Non-alcoholic Fatty Liver Disease (NAFLD) in Bariatric Patients
    Kanakala, V.
    Chattopadhyay, D.
    Sarkar, R.
    Balupuri, S.
    Small, P. K.
    BRITISH JOURNAL OF SURGERY, 2015, 102 : 285 - 285
  • [43] Lactobacillus rhamnosus GG Protects against Non-Alcoholic Fatty Liver Disease in Mice
    Ritze, Yvonne
    Bardos, Gyoengyi
    Claus, Anke
    Ehrmann, Veronika
    Bergheim, Ina
    Schwiertz, Andreas
    Bischoff, Stephan C.
    PLOS ONE, 2014, 9 (01):
  • [44] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
    Schattenberg, Joern M.
    ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
  • [45] Voluntary Distance Running Prevents Disease Progression in Mice with Non-Alcoholic Fatty Liver Disease (NAFLD).
    Gehrke, Nadine
    Biedenbach, Jana
    Huber, Yvonne
    Simon, Perikles
    Schuppan, Detlef
    Woerns, Marcus-Alexander
    Galle, Peter R.
    Schattenberg, Joern M.
    HEPATOLOGY, 2018, 68 : 758A - 758A
  • [46] In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kanuri, Giridhar
    Bergheim, Ina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (06): : 11963 - 11980
  • [47] Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
    Cole, Banumathi K.
    Feaver, Ryan E.
    Wamhoff, Brian R.
    Dash, Ajit
    EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (02) : 193 - 205
  • [48] Non-alcoholic fatty liver disease (NAFLD) among underweight adults
    Fahim, Shah Mohammad
    Chowdhury, Muhammad Abdul Baker
    Alam, Shahinul
    CLINICAL NUTRITION ESPEN, 2020, 38 : 80 - 85
  • [49] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course
    Cortez-Pinto, H
    Camilo, ME
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1089 - 1104
  • [50] Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
    Klein, Thomas
    Mark, Michael
    DIABETES, 2012, 61 : A265 - A266